Journal
LIFE-BASEL
Volume 13, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/life13040959
Keywords
oritavancin; long-acting; Gram-positive; vascular infections; prosthetic infections; device infections; enterococcal infections; review
Categories
Ask authors/readers for more resources
Oritavancin is a long-acting lipoglycopeptide with good antimicrobial activity against Gram-positive pathogens. It has been approved for acute bacterial skin and skin structure infections, but there are potential off-label uses for other infections. This review focuses on the real-life applications of oritavancin in infective endocarditis, catheter- or device-related infections, bloodstream infections, and bone and prosthetic joint infections, as well as potential future applications. Further studies are needed to evaluate the safety and effectiveness of oritavancin in various infections and resistant bacteria.
Oritavancin is a long-acting lipoglycopeptide with in vitro activity against Gram-positive pathogens, as well as good bactericidal activity and sterilisation ability in biofilm. It has been approved for acute bacterial skin and skin structure infections (ABSSSI), but recent reports have demonstrated possible off-label uses, such as for vancomycin resistant enterococci (VRE), deep-seated infections including those involving prosthetic material and invasive infections. The aim of this work is to review the uses of oritavancin outside of ABSSSI, focusing on its real-life applications on infective endocarditis, catheter- or device-related infections, bloodstream infections, and bone and prosthetic joint infections in humans, as well as possible future applications. We performed a narrative review, collecting the literature published between 1 December 2002 and 1 November 2022 on PubMed and the Cochrane Library using the term 'oritavancin'. Available studies have shown how effective it is in different settings, suggesting an opportunity for step-down strategies or outpatient management of infections requiring a long duration of antibiotic treatment. So far, evidence is still scarce, and limited to a few studies and case reports, mostly focusing on Staphylococcus aureus as the major isolate. Concerns about fluid intake for dilution and interaction with coagulation markers also need to be taken into account. Further studies are required in order to assess the safety and effectiveness of Oritavancin in vascular, prosthetic, or device-related infections, as well as in resistant Gram-positive bacteria or enterococcal infections.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available